Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

4D Molecular Therapeutics (FDMT) Return on Assets: 2021-2025

Historic Return on Assets for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to -0.47%.

  • 4D Molecular Therapeutics' Return on Assets fell 23.00% to -0.47% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.47%, marking a year-over-year decrease of 23.00%. This contributed to the annual value of -0.36% for FY2024, which is 2.00% down from last year.
  • 4D Molecular Therapeutics' Return on Assets amounted to -0.47% in Q3 2025, which was down 17.53% from -0.40% recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Return on Assets ranged from a high of -0.18% in Q2 2024 and a low of -0.47% during Q3 2025.
  • Over the past 3 years, 4D Molecular Therapeutics' median Return on Assets value was -0.29% (recorded in 2023), while the average stood at -0.31%.
  • Its Return on Assets has fluctuated over the past 5 years, first rose by 22bps in 2024, then declined by 23bps in 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Return on Assets (Quarterly) stood at -0.24% in 2021, then fell by 16bps to -0.40% in 2022, then climbed by 11bps to -0.29% in 2023, then grew by 1bps to -0.28% in 2024, then dropped by 23bps to -0.47% in 2025.
  • Its Return on Assets was -0.47% in Q3 2025, compared to -0.40% in Q2 2025 and -0.33% in Q1 2025.